ALMRAlamar Biosciences, Inc.
Next earnings ≈ Aug 7, 2026 · est. from filing cadence
Last earnings +1.3% on 2026-05-08
$28.42
▲ +7.33%$28.42▲ +67.18%
over 1Y
L $17.00H $28.42
Our buy Our hold Our sell Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today
+7.3%
1W
+10.8%
1M
+32.1%
3M
+67.2%
YTD
+67.2%
1Y
+67.2%
Mixed signals in the latest filings.
This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow ALMR (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call
Alamar Biosciences, Inc. shows limited reported revenue.
On these fundamentals, ALMR screens as SELL on the SEC figures.
Is ALMR a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 28 @ ~2.76 est
- Short put 26 @ ~1.82 est
debit $94max +$106max −$94BE 27.06
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Key statistics
Valuation
Enterprise value$1.97B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timelineSEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗SCHEDULE 13D/AFiling2026-07-07open ↗SCHEDULE 13GFiling2026-07-02open ↗10-QPeriod ending 2026-03-312026-05-08open ↗8-KPeriod ending 2026-05-082026-05-08open ↗SCHEDULE 13DFiling2026-04-23open ↗SCHEDULE 13DFiling2026-04-23open ↗4Period ending 2026-04-202026-04-22open ↗EFFECTFiling2026-04-20open ↗4Period ending 2026-04-162026-04-20open ↗4Period ending 2026-04-202026-04-20open ↗4Period ending 2026-04-202026-04-20open ↗4Period ending 2026-04-162026-04-20open ↗
Frequently asked
- Is Alamar Biosciences, Inc. (ALMR) a buy?
- ALMR currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
New filings change verdicts
The daily Brief delivers our freshest calls, rating flips and the filings behind them — every morning, free.
Sources: SEC EDGAR (CIK 0002104204, latest 10-Q filed 2026-05-08) · EODHD · as of 7/12/2026, 11:12:46 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 12, 2026, 7:12 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.